Nesiritide in Resistant Hypertension

Summary

Nesiritide in Resistant Hypertension is a clinical trial^[1].

Key Facts

• Nesiritide in Resistant Hypertension is in the country of United States^[2].
• Nesiritide in Resistant Hypertension's instance of is recorded as clinical trial^[3].
• Nesiritide in Resistant Hypertension's start time is recorded as +2012-04-30T00:00:00Z^[4].
• Nesiritide in Resistant Hypertension's end time is recorded as +2014-07-31T00:00:00Z^[5].
• Nesiritide in Resistant Hypertension's sponsor is recorded as John C. Burnett^[6].
• Nesiritide in Resistant Hypertension's main subject is recorded as arterial hypertension^[7].
• Nesiritide in Resistant Hypertension's number of participants is recorded as {'unit': '1', 'amount': '+12'}^[8].
• Nesiritide in Resistant Hypertension's title is recorded as Novel Peptides in Resistant Human Hypertension^[9].
• Nesiritide in Resistant Hypertension's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Nesiritide in Resistant Hypertension's ClinicalTrials.gov ID is recorded as NCT01514357^[11].
• Nesiritide in Resistant Hypertension's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}^[12].
• Nesiritide in Resistant Hypertension's research intervention is recorded as Natriuretic peptide, brain type^[13].
• Nesiritide in Resistant Hypertension's clinical trial phase is recorded as phase I clinical trial^[14].
• Nesiritide in Resistant Hypertension's clinical trial phase is recorded as phase II clinical trial^[15].
• Nesiritide in Resistant Hypertension's research site is recorded as Mayo Clinic^[16].
• Nesiritide in Resistant Hypertension's research subject recruitment status is recorded as terminated^[17].
• Nesiritide in Resistant Hypertension's study type is recorded as interventional study^[18].